drugset
drugset / Trial / NCT04626024

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024 ↗

Phase 2 Active not recruiting 17 enrolled Baylor College of Medicine
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

Timeline

Start
2020-12-22
Primary completion
2028-11-15
Completion
2028-11-15

Drugs

EvaluationDrugModalityDoseRoute
Background Bosutinib Small molecule — —
Background Imatinib Small molecule — —
Background Nilotinib Small molecule — —
Background dasatinib anhydrous Small molecule — —

Indications

chronic myeloid leukemia